Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orion InfusionsDHA:ORIONINFU +0.94%83 Debt-to-EBITDA is 6.15 as of Mar. 2026, which is 102% above its 10-year median of 3.05. GuruFocus rates DHA:ORIONINFU with a GF Score™ of 83/100 and a GF Value™ of BDT314.51 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 683 Drug Manufacturers companies, Orion Infusions ranks worse than 68.37% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Orion Infusions's Debt-to-EBITDA or its related term are showing as below:
DHA:ORIONINFU'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 2.48 Med: 3.05 Max: 3.98
Current: 3.04
During the past 13 years, the highest Debt-to-EBITDA Ratio of Orion Infusions was 3.98. The lowest was 2.48. And the median was 3.05.
DHA:ORIONINFU's Debt-to-EBITDA is ranked worse than 68.37% of 683
companies
in the Drug Manufacturers industry
Industry Median: 1.63
vs DHA:ORIONINFU: 3.04
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Orion Infusions Debt-to-EBITDA Related Terms
Orion Infusions Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Orion Infusions's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ORIONINFU vs ZTS, UTHR, VTRS: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Orion Infusions's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Infusions Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orion Infusions's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Orion Infusions's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Orion Infusions (DHA:ORIONINFU) has a Debt-to-EBITDA of 6.15 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Orion Infusions. This is 102% above median its historical median of 3.05. Over the past decade, Orion Infusions' Debt-to-EBITDA has ranged from 2.48 to 3.98. According to the industry distribution chart, Orion Infusions ranks #467 out of 683 companies in the Drug Manufacturers industry, placing it in the top 68.4%.
Is Orion Infusions' Debt-to-EBITDA too high?
Orion Infusions' current Debt-to-EBITDA of 6.15 is 102% above median its 10-year median of 3.05. Over the past 10 years, this metric has ranged from a low of 2.48 to a high of 3.98. The Drug Manufacturers industry median Debt-to-EBITDA is 1.63. Orion Infusions' value of 6.15 is 277.3% above this industry median. Based on the distribution chart, Orion Infusions ranks #467 out of 683 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Orion Infusions has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Orion Infusions' Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Orion Infusions ranks #467 out of 683 companies for Debt-to-EBITDA. This places Orion Infusions in the lower half of its industry. The industry median Debt-to-EBITDA is 1.63. Orion Infusions' value of 6.15 is 277.3% above this benchmark. Historically, Orion Infusions' own Debt-to-EBITDA has ranged from 2.48 to 3.98 over the past decade. While the company's 10-year median is 3.05 vs. the industry median of 1.63, Orion Infusions has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.63, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orion Infusions's current Debt-to-EBITDA of 6.15 is 277.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Orion Infusions. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Infusions's current Debt-to-EBITDA is 6.15, which is 102% above median its own 10-year median of 3.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Infusions stock overvalued right now?
Based on GuruFocus' analysis, Orion Infusions (DHA:ORIONINFU) is currently considered Modestly Undervalued. The stock's GF Value™ is BDT314.51, compared to a current price of BDT267.20 — trading 15% below its estimated fair value. The current Debt-to-EBITDA is 6.15, which is 102% above median its 10-year median of 3.05 and 277.3% above the Drug Manufacturers industry median of 1.63. Orion Infusions' overall GF Score™ is 83/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Orion Infusions (DHA:ORIONINFU), the current Debt-to-EBITDA is 6.15 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Infusions (DHA:ORIONINFU) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Infusions stock appears to be undervalued.
The current stock price of BDT267.20 is trading 15% below its estimated GF Value™ of BDT314.51.
GuruFocus considers Orion Infusions to be Modestly Undervalued.
Key valuation signals for DHA:ORIONINFU:
Debt-to-EBITDA: 6.15 (102% above median its 10-year median of 3.05)
GF Value™: BDT314.51 vs. price of BDT267.20 (15% below fair value)
Industry Position: 277.3% above the Drug Manufacturers median (#467 of 683)
No single metric tells the full story. See the DHA:ORIONINFU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Infusions Ltd is a pharmaceutical company engaged in the production of various types of intravenous fluids, rehydration solutions, electrolyte solutions, and solutions for acidosis, as well as Ranitidine I.V. infusion and anti-microbial products such as Ciprofloxacin I.V. and Metronidazole I.V. The Company's products include Dextrolac, Dextropac, Dextrosal, Dianak, Electro Dex, Fructose, Hartman, Intralipid, Manisol, Maprocin, Nidazyl, Orlev, Ortac, Plasmasol, Proliv, and Salpac. In addition, the Group operates across several sectors, including pharma and healthcare, power and energy, infrastructure development, real estate, cosmetics and toiletries, consumer products, textiles and garments, and home appliances. Geographically, the Company operates in Bangladesh.
83GF Score
Get the complete analysis for DHA:ORIONINFU
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ORIONINFU has been successfully added to your 
